Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198147 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11F2POLBHTT | |
| SCHEMBL198340 | 0.87 | GPR132 (0.36) | CYP4F2CYP4A11HTTTDP1HDAC6 | |
| SCHEMBL198148 | 0.81 | CYP4F2 (0.32) | CYP4F2CYP4A11F2POLBHTT | |
| SCHEMBL2808491 | 0.77 | VNN1 (0.39) | CYP4F2CYP4A11HDAC3HDAC1HDAC2 | |
| SCHEMBL2808488 | 0.77 | VNN1 (0.39) | CYP4F2CYP4A11HDAC3HDAC1HDAC2 | |
| SCHEMBL2808923 | 0.75 | CYP4F2 (0.40) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL2808925 | 0.75 | CYP4F2 (0.40) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL2812645 | 0.75 | HDAC3 (0.41) | CYP4F2CYP4A11HDAC3HDAC1HDAC2 | |
| SCHEMBL184726 | 0.75 | HDAC3 (0.41) | CYP4F2CYP4A11HDAC3HDAC1HDAC2 | |
| SCHEMBL185854 | 0.75 | KDM4E (0.45) | CYP4F2CYP4A11GPR132CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CYP4F2 874/4885CYP4A11 223/4885F2 677/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CYP4F2 874/4885CYP4A11 223/4885F2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.